InsiderTradesSIGMA

PicksTOP Companies Executives Performance Blog Topics

InsidersTradesSigma

InsiderTradesSIGMA

Multi-market insider intelligence. Official public filings, re-aggregated and scored. Private beta.

FRUSDEGBCHCAITESNLBENOSEFIDKAUATIEBRINJP+ 8 markets

Recommendations
Companies
Insiders
Performance
Backtest
Compare

Methodology
How it works
Glossary
API docs
Status
Blog

Sign in
Create account
Portfolio
API keys
Alerts
Upgrade

Privacy
Terms
Cookies
Contact
About

Built in Paris. Public sources across 28 markets: AMF France, SEC EDGAR Form 4 US, BaFin Germany, SIX SER Switzerland, RNS United Kingdom, SEDI Canada, Consob Italy, CNMV Spain, AFM Netherlands, FSMA Belgium, Oslo Bors Norway, Nasdaq Helsinki, Nasdaq Copenhagen, ASX Australia, FMA Austria, CVM Brazil, HKEX Hong Kong, BSE-Sofia Bulgaria, Tadawul Saudi Arabia, DART South Korea, EDINET Japan, SSE and SZSE China, SEBI India, KNF Poland, PSE Philippines, NZX New Zealand, JSE South Africa. Prices + fundamentals via Yahoo Finance, STOXX 600 sector ETFs (iShares Xetra). Stack: Next.js 16, Prisma, Vercel. Live out-of-sample tracker since 2026-05-16. Methodology audits: /methodologie and /docs/method-review/.

Sources: official public filings under MAR Art.19 (EU and EEA), SEC Section 16 / Form 4 (US), Art.56 SESTA (CH, SIX SER), NI 55-104 / SEDI (CA), Corporations Act s205G (AU) and equivalent regimes. Signals on this site are for educational use only and do not constitute investment advice within the meaning of MiFID II / SEC Reg-IA. Past performance does not guarantee future results. Swiss SIX SER filings are anonymised by law (role only, no name).

Theme: dark (range regime detected on CAC40 90d · as of 2026-05-25)

© 2026 Insiders TradesΣ·Private beta·Hosted on Vercel

All systems operational

InsidersTradesSigma

Y.T.S Prasad — personal trades · 16 disclosures

← Executives ★ Sign in to follow

YP

Y.T.S Prasad

ININ·SEBI (PIT + SAST)

Divi's Laboratories Limited

Cumul. flow

0

Total declarations

0

Company

—

▲ Purchases (0 ops.)

—

▼ Sales (0 ops.)

Discover the full record of transactions filed by Y.T.S Prasad. Insider active across 1 companies, notably Divi's Laboratories Limited. Cumulatively, 16 filings have been recorded. The latest transaction was filed on 28 March 2024 — Pledge. Regulator: SEBI (PIT + SAST). The full history is free.

Declarations16 total

Executives●PledgeDDivi's Laboratories Limited0SEBI

Y

€1m27,000 shares@ €37.649

Equity Shares

SEBI:fc49a7933b1a2c44d0a29fd7089206b7a689c189·28 Mar 2024

Executives●PledgeDDivi's Laboratories Limited0SEBI

Y

€933,69424,800 shares@ €37.649

Equity Shares

SEBI:0c32fea754f96442e3adb89cf40660da91be14f1·28 Mar 2024

Executives●PledgeDDivi's Laboratories Limited0SEBI

Y

€116,6033,700 shares@ €31.5143

Equity Shares

SEBI:a2ffe34e6a908fb7fe4b1b803b04ad3c975ba7e3·15 Mar 2023

Executives●SaleDDivi's Laboratories Limited0SEBI

Y

€134,7234,275 shares@ €31.5143

Equity Shares

SEBI:968d92147522aabb934dcbf5c39d233ca1cacd80·15 Mar 2023

Executives●SaleDDivi's Laboratories Limited0SEBI

Y

€26,216815 shares@ €32.1669

Equity Shares

SEBI:2d1f0ef59f3192c571a9b0c03ed2b7fa5839cd05·10 Mar 2023

Executives●SaleDDivi's Laboratories Limited0SEBI

Y

€32,7691,000 shares@ €32.7687

Equity Shares

SEBI:0b0e900b00a152f28c8ff588238cac521ff267fe·6 Mar 2023

Executives●PledgeDDivi's Laboratories Limited0SEBI

Y

€326,33710,000 shares@ €32.6337

Equity Shares

SEBI:9b940f28f238282ce18029472000b62ac80f8958·7 Feb 2023

Executives●SaleDDivi's Laboratories Limited0SEBI

Y

€315,05010,000 shares@ €31.505

Equity Shares

SEBI:a16ba57bab175f86b545e8851a03158046edfa2f·7 Feb 2023

Executives●SaleDDivi's Laboratories Limited0SEBI

Y

€94,1162,000 shares@ €47.0578

Equity Shares

SEBI:6d68c100a37ce76a58e1958686c845919621b806·28 Sept 2022

Executives●PledgeDDivi's Laboratories Limited0SEBI

Y

€263,9386,475 shares@ €40.7626

Equity Shares

SEBI:5452f7e540cef4d267e89c95325c9ef7b9c7d24c·26 May 2022

Executives●PledgeDDivi's Laboratories Limited0SEBI

Y

€167,8943,175 shares@ €52.8799

Equity Shares

SEBI:e99c70d3a758d29b86133c9cf83b232cd4f709a9·22 Mar 2022

Executives●PurchaseDDivi's Laboratories Limited0SEBI

Y

030,000 shares

Equity Shares

SEBI:6bb98526929d5feb838eba22e3e196fce78d1600·16 Feb 2022

Ideal exit: 13 Nov 2022 (T+270)

Executives●SaleDDivi's Laboratories Limited0SEBI

Y

€88,2011,700 shares@ €51.8828

Equity Shares

SEBI:b9a7477515d2196bde32d1664a95423889dff32a·20 Dec 2021

Executives●SaleDDivi's Laboratories Limited0SEBI

Y

€17,645300 shares@ €58.8181

Equity Shares

SEBI:25e939198a940c8549e68ba94696f349856dc772·26 Nov 2021

Executives●SaleDDivi's Laboratories Limited0SEBI

Y

€98,4771,700 shares@ €57.9275

Equity Shares

SEBI:5eb05db3baa3fb85cab88fc9e354dc6a2c75d4b1·29 Nov 2021

Executives●SaleDDivi's Laboratories Limited0SEBI

Y

€56,1791,000 shares@ €56.1785

Equity Shares

SEBI:3c93084b9666655c98521a818c15ead9506b364c·22 Nov 2021

16 of 16 declarations